ライフサイエンスコーパス: medullary thyroid carcinoma

1 uals (2 patients died of causes unrelated to medullary thyroid carcinoma).

2 ogene and virtually all of them will develop medullary thyroid carcinoma.

3 ne in the TT cell line, derived from a human medullary thyroid carcinoma.

4 L881V) mutation previously found in familial medullary thyroid carcinoma.

5 rine neoplasia types 2A and 2B, and familial medullary thyroid carcinoma.

6 ociated with the risk of developing sporadic medullary thyroid carcinoma.

7 the RET proto-oncogene could prevent or cure medullary thyroid carcinoma.

8 MEN) type 2A (MEN-2A) or type 2B or familial medullary thyroid carcinoma.

9 pillary carcinoma, follicular carcinoma, and medullary thyroid carcinoma.

10 s of the RET proto-oncogene cause hereditary medullary thyroid carcinoma.

11 mehow play a role in the genesis of sporadic medullary thyroid carcinoma.

12 ession of pituitary anterior lobe tumors and medullary thyroid carcinomas.

13 t frequently mutated malignant subtypes were medullary thyroid carcinoma (9/12, 75%) and PTC (14/30,

14 cer predisposition syndrome characterized by medullary thyroid carcinoma, a tumour of the calcitonin-

15 Medullary thyroid carcinoma accounts for 2% to 5% of thy

16 o other conditions including MEN2A, familial medullary thyroid carcinoma and intestinal aganglionosis

17 nical management of patients with metastatic medullary thyroid carcinoma and other CCK2R-expressing m

18 The MEN 2 syndromes are characterized by medullary thyroid carcinoma and other endocrinopathies.

19 The review focuses first on medullary thyroid carcinoma and performing prophylactic

20 explain the increased expression of CAIX in medullary thyroid carcinoma and provide a rationale for

21 ds resected at the time of thyroidectomy for medullary thyroid carcinoma and transplanted in the nond

22 actor receptor) occur in nearly all familial medullary thyroid carcinomas and may be used for family

23 ce of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events

24 l in patients with progressive or metastatic medullary thyroid carcinoma, as well as other advanced-s

25 2 (MEN 2A, MEN 2B and familial MTC) all have medullary thyroid carcinoma, but vary in the involvement

26 fied from conditioned medium of cultured rat medullary thyroid carcinoma CA-77 cells.

27 tion factor, RREB-1, was cloned from a human medullary thyroid carcinoma cell line.

28 ilar expression pattern was recapitulated in medullary thyroid carcinoma cells in vivo, consistent wi

29 that in control individuals without sporadic medullary thyroid carcinoma (Fisher's exact test, P = 0.

30 A had no evidence of persistent or recurrent medullary thyroid carcinoma five or more years after tot

31 crine neoplasia type 2A (MEN2A) and familial medullary thyroid carcinoma (FMTC) carry germ-line point

32 In this study, we have shown that familial medullary thyroid carcinoma (FMTC) mutants RET(Y791F) an

33 ndocrine neoplasia (MEN) 2A and 2B, familial medullary thyroid carcinoma (FMTC), and Hirschsprung's d

34 s 2A and 2B (MEN 2A and MEN 2B) and familial medullary thyroid carcinoma (FMTC), as well as some case

35 (RET) gene cause MEN2A, MEN2B, and familial medullary thyroid carcinoma (FMTC).

36 r the development of the hereditary forms of medullary thyroid carcinoma has simplified management an

37 We also assessed remission of medullary thyroid carcinoma, incidence and treatment of

38 Medullary thyroid carcinoma is a relatively rare tumor w

39 Medullary thyroid carcinoma is a tumor of neuroendocrine

40 Medullary thyroid carcinoma is the most common cause of

41 The aetiology of sporadic medullary thyroid carcinoma is unknown.

42 In Rb1(+/-)Nras(+/-) animals, distant medullary thyroid carcinoma metastases are associated wi

43 receptor (CCK2R) targeting in patients with medullary thyroid carcinoma (MTC) and other neuroendocri

44 nase, are associated with the development of medullary thyroid carcinoma (MTC) and pathogenesis of mu

45 In patients with medullary thyroid carcinoma (MTC) and type 2A multiple e

46 Patients with hereditary medullary thyroid carcinoma (MTC) associated with multip

47 Activation of Ras or Raf in the human medullary thyroid carcinoma (MTC) cell line, TT, induces

48 All of the cases of medullary thyroid carcinoma (MTC) express the RET recept

49 screening can facilitate early detection of medullary thyroid carcinoma (MTC) in patients with patho

50 Medullary thyroid carcinoma (MTC) is a neuroendocrine ca

51 Medullary thyroid carcinoma (MTC) is a neuroendocrine tu

52 Medullary thyroid carcinoma (MTC) is a neuroendocrine tu

53 Medullary thyroid carcinoma (MTC) is a rare endocrine tu

54 Medullary thyroid carcinoma (MTC) is an aggressive neuro

55 Treatment of patients with advanced medullary thyroid carcinoma (MTC) is still a challenge.

56 ized in a first-in-humans study performed on medullary thyroid carcinoma (MTC) patients (the iPET-MTC

57 Sequencing for Familial Colon Cancer Genes, Medullary Thyroid Carcinoma (MTC) Surveillance Study, Os

58 The prognosis of medullary thyroid carcinoma (MTC) varies from long- to s

59 AIR) differentiated thyroid carcinoma (DTC), medullary thyroid carcinoma (MTC), and anaplastic thyroi

60 In contrast to the hereditary form of medullary thyroid carcinoma (MTC), little is known about

61 tudy is to determine whether reoperation for medullary thyroid carcinoma (MTC), performed with low mo

62 n inherited cancer syndrome characterized by medullary thyroid carcinoma (MTC), pheochromocytoma (PC)

63 ed subtypes include MEN 2A, characterized by medullary thyroid carcinoma (MTC), pheochromocytoma (phe

64 idectomy, thus preventing the development of medullary thyroid carcinoma (MTC), the dominant endocrin

65 ene have been found in familial and sporadic medullary thyroid carcinoma (MTC), the molecular events

66 efines these 2 phenotypes is the presence of medullary thyroid carcinoma (MTC).

67 d peptides labeled with (111)In or (131)I in medullary thyroid carcinoma (MTC).

68 effective therapy for patients with advanced medullary thyroid carcinoma (MTC).

69 ble in patients with biochemical evidence of medullary thyroid carcinoma (MTC).

70 rapy for patients with distant metastasis of medullary thyroid carcinoma (MTC).

71 crine neoplasia type 2 (MEN 2) that includes medullary thyroid carcinoma (MTC).

72 e are associated with inherited and sporadic medullary thyroid carcinoma (MTC).

73 to induce neuroendocrine differentiation of medullary thyroid carcinoma (MTC, malignant C cell tumor

74 Medullary thyroid carcinomas (MTC), a tumor of the thyro

75 on benign (pheochromocytomas) and malignant (medullary thyroid carcinomas, MTCs) tumors from patients

76 For medullary thyroid carcinoma, near-total and total thyroi

77 (4q32A>C) in a large pedigree displaying non-medullary thyroid carcinoma (NMTC).

78 crine neoplasia types IIA, IIB, and familial medullary thyroid carcinoma not associated with multiple

79 germline RET mutation, and characterised by medullary thyroid carcinoma, phaeochromocytoma, and extr

80 syndrome characterized by the development of medullary thyroid carcinoma, pheochromocytomas, musculos

81 ives were to determine overall survival, and medullary thyroid carcinoma-specific survival based on w

82 Medullary thyroid carcinoma-specific survival curves did

83 ic carcinomas, and its expression pattern in medullary thyroid carcinomas suggested contribution of b

84 he myeloid cell lineage in patients with non-medullary thyroid carcinoma (TC) and multinodular goiter

85 onal activation of mutated RET gene in human medullary thyroid carcinoma TT cells.

86 or predispose to the development of sporadic medullary thyroid carcinoma, we analysed genomic DNA fro

87 h familial, non-multiple endocrine neoplasia medullary thyroid carcinoma will provide information tha

88 However, it also promotes the development of medullary thyroid carcinomas yielding metastases at a hi